Graham Holdings Company Common Stock vs TransMedics Group Inc — how do they compare? Graham Holdings Company Common Stock trades at $1,190.11 (market cap $4.97B), while TransMedics Group Inc trades at $75.46 (market cap $2.74B). The key difference: Graham Holdings Company Common Stock is the larger of the two by market cap, and Graham Holdings Company Common Stock pays a 0.64% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Graham Holdings Company Common Stock for 0 Days and TransMedics Group Inc for 24 Days on average.
| GHC | TMDX | |
|---|---|---|
Market Cap | $4.97B | $2.74B |
Volume | 27,383 | 1,025,926 |
Sector | Industrials | Health |
52-Week High | $1.23K | $150.42 |
52-Week Low | $949.84 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $5.06B | $3.14B |
Dividend Yield | 0.64% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMDX trades at $79.14, up 1.23% on the day, but faces a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Recent news highlights insider buying and a new CFO appointment, alongside multiple legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but near-term risks include earnings volatility, legal scrutiny, and a declining net cash flow trend. Investors should weigh solid fundamentals against execution and sentiment risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Graham Holdings Company is a diversified holding company with operations spanning education services (Kaplan), television broadcasting (Graham Media Group), healthcare services, and manufacturing, among other businesses; it was formerly known as The Washington Post Company.
Read more on GHC →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →